| The Characterization and Treatment of Aggressive Breast Cancer |
MAY 2007 |
72 pages |
| Authors:
Rita Nanda; CHICAGO UNIV IL MEDICAL SCHOOL
|
 | Several groups have demonstrated that women with BRCA1 germline mutations are more likely to have breast cancers that are basal-like by gene expression profiling. While BRCA1 germline mutations are uncommon and contribute to fewer than 5% of breast cancers our lab has demonstrated that methylation occurs in up to 50% of high-grade hormone receptor negative sporadic tumors. As promoter methylation leads to transcriptional repression we propose that such tumors will ... |
|
| The Characterization and Treatment of Aggressive Breast Cancer |
May 2006 |
15 pages |
| Authors:
Rita Nanda; CHICAGO UNIV IL
|
| Several groups have demonstrated that women with BRCA1 germline mutations are more likely to have breast cancers that are basal-like by gene expression profiling. While BRCA1 germline mutations are uncommon, and contribute to fewer than 5% of breast cancer cases, our lab has demonstrated that methylation of the BRCA1 promoter occurs to some degree in almost 50% of high-grade, hormone receptor negative sporadic tumors. As promoter methylation leads to transcriptional ... |
|
| The Characterization and Treatment of Aggressive Breast Cancer |
MAY 2005 |
55 pages |
| Authors:
Rita Nanda; CHICAGO UNIV IL
|
| Several groups have demonstrated that women with BRCA1 mutations are more likely to have breast cancers that are hormone receptor and HER2/neu negative. Our lab has previously demonstrated that BRCA1 promoter methylation occurs to some degree in 30% of all sporadic tumors, and up to 50% of high-grade hormone receptor negative tumors, making it much more common than germline mutation. Given the role of BRCA1 in DNA repair, it is ... |
|
Reports by Author
